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1INTRODUCTION
Metabolic syndrome is one of the health issues of this century. It
is a constellation of physical conditions and metabolic abnormalities
commonly occurring together, that increases the individuals risk for the
development of type 2 diabetes mellitus and cardiovascular disease. If
the current trend continues the premature deaths and disabilities
resulting from these conditions will increase the financial burden in
developed and developing countries.1
As the prevalence of metabolic syndrome is high worldwide and
increasing day by day due to sedentary lifestyle the findings of the
present study has important implications for clinical practice emphasis
must be placed on the intake of balanced diet and the control of lipid
level particularly that of triglycerides.
2AIM
To ascertain the prevalence of metabolic syndrome in patients
with acute coronary syndrome and to find out the association of each
component of metabolic syndrome with acute coronary syndrome.
3REVIEW OF LITERATURE
Definition of metabolic syndrome
It is defined as clustering of cardiovascular risk factors in an
individual which predisposes the person to a greater risk of developing
type 2 diabetes mellitus and cardiovascular disease.
It was first termed as syndrome X in 1988.
Main feature of metabolic syndrome includes insulin resistance.
Criteria for diagnosis
International disease federation
WHO criteria
National cholesterol education panel ATP III guidelines.
4HISTORY OF METABOLIC SYNDROME
The term "metabolic syndrome" dates back to at least the late 1950s,
but came into common usage in the late 1970s to describe various
associations of risk factors with diabetes that had been noted as early as
the 1920s
The Marseilles physician Dr. Jean Vague, in 1947, observed that upper
body obesity appeared to predispose to diabetes, atherosclerosis, gout
and calculi.
Avogadro, Crepaldi and co-workers described six moderately obese
patients with diabetes, hypercholesterolemia, and marked
hypertriglyceridemia all of which improved when the patients were put
on a hypocaloric, low-carbohydrate diet.
In 1977, Haller used the term "metabolic syndrome" for associations of
obesity, diabetes mellitus, hyperlipoproteinemia, hyperuricemia, and
hepatic steatosis when describing the additive effects of risk factors on
atherosclerosis.
The same year, Singer used the term for associations of obesity, gout,
diabetes mellitus, and hypertension with hyperlipoprotenemia.
In 1977 and 1978, Gerald B. Phillips developed the concept that risk
factors for myocardial infarction concur to form a "constellation of
abnormalities" (i.e., glucose intolerance, hyperinsulinemia,
hypercholesterolemia, hypertriglyceridemia, and hypertension) that is
associated not only with heart disease but also with aging, obesity and
other clinical states. He suggested there must be an underlying linking
factor, the identification of which could lead to the prevention of
cardiovascular disease; he hypothesized that this factor was sex
hormones.
In 1988, in his Banting lecture, Gerald M. Reaven proposed insulin
resistance as the underlying factor and named the constellation of
abnormalities Syndrome X. Reaven did not include abdominal obesity,
which has also been hypothesized as the underlying factor, as part of
the condition.
5PREVALENCE OF METABOLIC SYNDROME
Highest Prevalence worldwide  is in native Americans with nearly
60%of women ages 45-49 and  45% of men ages 45-49 meeting
national cholesterol education program ,adult treatment panel III.
Based on data from the national health and nutrition examination
survey the age adjusted prevalence of metabolic syndrome in united
states is 34% for men and 35% for women.
Prevalence of metabolic syndrome in patients with coronary heart
disease is 50% 2
Prevalence of metabolic syndrome  in patients with premature
coronary artery disease  is 37%(age<45 years).
Total prevalence of metabolic syndrome in asian Indians residing
in India.
Author,year city Prevalence
Kasliwal et al;2005,Delhi 28.5
Gupta  et al ;2004 Jaipur 25
Misra et al ;2004 Delhi 12
Ramachandran et al 2005;Chennai 41
The prevalence of metabolic syndrome in patients with acute coronary
syndrome in a study conducted in 2010 in middle east countries was
around 46%.
6National cholestrol education panel 2001 adult treatment panel
III provided a new definition for metabolic syndrome according to
which a person must have three of the following five abnormalities.
Central obesity : waist circumference >102 cm (M),88 cm (F)
Hypertriglyceridemia : triglycerides >150 mg/dl  or specific
medication.
Low HDL cholesterol :<40 mg/dl and <50 mg/dl or specific
medication.
Hypertension :blood pressure  >130 mm systolic or.85 mm
diastolic or specific medication.
Fasting plasma glucose level >100 mg/dl  or specific medication
or previously diagnosed type 2 diabetes.
These guidelines assert that abdominal obesity rather than
elevated body mass index is highly associated with metabolic
syndrome.
ATP  III   has  a  lower  diagnostic  threshold  level  than  WHO   for
certain characteristics HDL cholesterol and hypertension therefore
higher proportion of the population meets ATP III rather than WHO
guidelines.
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Obesity in Metabolic Syndrome
Excess adipose tissue loaded with lipids (obesity) produces
abnormal amounts of NEFA & other adipokines like adiponectin,
leptin, PAI-1, resistin, TNF-? , IL - 6 and other inflammmatory
cytokines. The protective adiponectin is produced in subnormal
amounts in obese persons. These abnormal products of adipose tissue
flood various key tissues and in turn give rise to metabolic syndrome .
Cause of Hypertension in metabolic syndrome is complex and
multifactorial and all of the elements of metabolic syndrome including
obesity, Insulin Resistance, dyslipidemia probably are involved in
mediating changes ultimately resulting in Hypertension & modifying its
course
8WHO 1999 3
Diabetes or impaired fasting glycemia or impaired glucose tolerance or
insulin resistance plus two or more of the following
Obesity-body mass index >30 kg/m2 Or
waist  hip ratio>0.9 in males or>0.85 in females.
Dyslipidemia-triglycerides>150 mmol/l or HDL<0.9(males) or <1
mmol/l in females.
Hypertension-BP>140/90 mm/hg
Microalbuminuria-albumin excretion>20 micro gram/min.
9Risk Factors IDF consensus (2005) ATPIII criteria (2001) WHO criteria (1999)
10
Metabolic syndrome is also known as 4
Metabolic syndrome X
Dysmetabolic syndrome
Insulin resistance syndrome
Reavens syndrome
Cardiometabolic syndrome
Beer belly syndrome
Etiology
Insulin resistance
Leptin resistance
Sympathetic overactivity
Endocannabinoid system overactivity
Reduced serotonergic responsivity.
12
Endocannabinoid system overactivity
Endo cannabinoid system signaling occurs in adipose tissue,liver,GIT
and centrally within the brain.overactivation of endocannabinoid
system lead to weight gain,lipogenesis,insulin resistance,dyslipidemia
and impaired glucose haemostasis.
Sympathetic overactivity
Environmental factors activate brain centres causing frequent
hypothalamic arousal via hypothalamic pituitary axis leading to
elevated cortisol levels which induces the metabolic syndrome.
11
Insulin resistance
Insulin resistance is a precursor of type 2 diabetes mellitus. The
homeostasis model  assessment of insulin resistance takes into account
both insulin levels and glycemia and is a more critical measure of
Insulin resistance.
Insulin resistance has been considered to be a pre atherosclerotic and
pre diabetic state.
Leptin resistance
Leptin the product of ob gene  is a protein secreted mainly by adipose
tissue which signals the size of energy stores to the central nervous
system modulating the activity of hypothalamic centres involved in
the regulation of food intake and energy balance..
other functions are immune function,,bone formation also enhances the
aggregation  of platelets.
Leptin attenuates the lipogenesis and oxidative actions of
insulin,increases the beta oxidation of nonesterified fatty acids and
decreases its esterification into triacylglycerol.
Leptin decreases lipogenesis and protects against tissue lipotoxicity.
High sustained concentration of leptin  from the enlarged adipose tissue
result in leptin desensitization
Leptin resistance also causes insulin resistance..Either leptin resistance
or decreased leptin  production by adipose tissue might potentially
contribute to the development of metabolic syndrome.
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RISK FACTORS
Obesity
Central adiposity is a key feature of this syndrome. However
patients with normal weight may also be insulin resistant and have this
syndrome (Ho et al;2001)6
Sedentary life style
Physical inactivity is a predictor of cardiovascular disease and
associated with metabolic risk factors.7
Age
Greater percentage of women greater than 50 years have the
syndrome than males. (Sung et al 2003) 8
Ethnicity
Higher prevalence of metabolic syndrome in non European
groups, south Asians, black Africans, Hispanics (mckeinge PM 1992).9
Genetic factors
Certain components of metabolic syndrome are strongly
associated with genetic inheritance triglycerides and glucose
intolerance. (poulsen et al 2001)10
Birth weight
Low birth weight  is associated with higher prevalence of
metabolic syndrome.(Yarbrough et al1998)11
14
Diet-Insulin resistance is inversely associated with whole grain
food, dietary fibres, cereal and fruit fibres. It is positively associated
with glycaemic index. (Framingham offspring study, mckewn et al
2004)12
Endocrine factors
Hyperandrogenemia, polycystic ovarian syndrome, low total
testosterone and SHBG levels, GH –IGF axis, glucocorticoid excess all
predict the development of metabolic syndrome and diabetes
(laaksonen et al).13
Inflammation
Chronic subclinical inflammation is associated with insulin
resistance in metabolic syndrome.14
Alcohol
Alcohol consumption is associated with increased triglycerides,
HDL and increased blood pressure. Therefore has different effects and
different aspects of metabolic syndrome.15
Comorbidity
In People with diabetes mellitus, hypertension, CHD the
prevalence of metabolic syndrome is higher.16
Among people with mental illness notably schizophrenia the
prevalence of metabolic syndrome is higher. Use of ART in HIV
patients is associated with high risk of metabolic syndrome.
Lipodystrophy both acquired and genetic causes predispose to
insulin resistance and to metabolic syndrome.
15
Pathogenesis
Sedentary life style and high dietary calorie intake leads to
decreased free fatty acids and glucose oxidation leading onto body fat
accumulation and resistance to biological action of insulin.
Obesity leads to increased secretion of proinflammatory
cytokines like tumour necrosis factor alpha, interleukin -6, interleukin
beta from adipose tissue. 17these cytokines causes
Decreased insulin induced suppression of glucose production.
Increased fatty acid cholesterol synthesis.
Increased hepatic VLDL production.
Increased adipocyte lipolysis. (nesto 2004)
Nonesterified fatty acids released in abundance from an
expanded adipose tissue mass.in the liver it tends to increase the
glucose and triacylglycerol production and secretion of VLDL .
Associated abnormalities are decrease in HDL and increase in
LDL cholesterol.
Nonesterified fatty acids also reduces insulin sensitivity in
muscles by inhibiting  insulin mediated glucose uptake leading to
decreased production of glycogen, increased insulin secretion resulting
in hyperinsulinemia.
Hyperinsulinemia leads to sodium reabsorption and increased
sympathetic nervous system activity leading to hypertension.
Increased adipocyte lysis leads to increased non esterified fatty acids 18
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It causes
Increased hepatic    triglyceride synthesis
Increased hepatic VLDL secretion
Reduced glucose uptake and oxidation.
Decrease in HDL
Increase in LDL
Increase in plasma glucose.
Effect of adiponectin in metabolic syndrome
Adiponectin secreted by adipocytes have its receptors in skeletal
muscles and liver .It has beneficial effects on insulin sensitivity, fat and
glucose metabolism.
It decreases the inflammatory pathway by reduction of nuclear
factor kappa activity. (Chandran et al) 19
Insulin resistance directly leads to endothelial dysfunction by
increasing expression of ICAM 1 and thereby increasing macrophage
attachment to endothelium. 20
Glucocorticoids
Many of the properties of glucocorticoid hormones are
antagonistic to the action of insulin. (filipovsky et al)21
Elevated plasma cortisol concentration are associated with high
blood pressure, glucose intolerance, insulin resistance and
hyperlipidemia.
17
Associations of metabolic syndrome 22
Visceral Obesity
Type 2 diabetes
Essential hypertension
Cardiovascular disease –myocardial infarction ,peripheral vascular
disease, stroke.
Carcinoma of breast, prostate, liver and colorectal cancer.
Fatty liver
Insulin resistance
Obstructive sleep apnea syndrome
Polycystic ovary syndrome
Acanthosis nigricans
Dementia
Hyperuricemia
Microalbuminuria.
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In Insulin Resistance, vasodilatory effect is lost but renal effect
on sodium reabsorption is preserved. Insulin action on increasing
sympathetic nervous system activity is also preserved. There  is  also  a
pathway specific inhibition of phosphatidylinositol - 3 – kinase
signaling leading to imbalance in production of Nitric Oxide and
Secretion of endothelin-1 contributing to decreased blood flow.
Insulin resistance and metabolic syndrome 23
Inherited causes include the very rare mutation affecting the
insulin receptor of post receptor signaling pathways which can lead to
extreme insulin resistance. .Milder polygenic defects contribute to the
Insulin resistance of type 2 diabetes . Insulin receptor mutations cause
clinically distinct syndromes often with acanthosis nigricans
And In women features of polycystic ovarian disease and
masculinization.
Specific syndromes include the speculatively named
leprachaunism and various inherited lipodystophies   in which fat is lost
from subcutaneous and other depots. Recently mutations affecting the
PPAR gamma gene have been shown to modify insulin sensitivity.
20
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Endothelial dysfunction
In metabolic syndrome, there is abnormal Nitric Oxide
metabolism that leads on to decreased endothelial Nitric Oxide
production. (venugopal et al) 24 There is a reduced vasodilatory
response to Insulin. (tack et al)25
Increased oxidative stress, inflammation and thrombosis are the
consequences of vasoconstriction due to increased endothelin and
Angiotensin. Abnormal nitric oxide metabolism also favours
vasoconstriction.
Inflammatory markers
There is an increase in proinflammatory cytokines including IL-
1, IL-6, IL-18, Resistin, TNF?, CRP due to overproduction by the
adipose tissue derived macrophages.
Among these markers, CRP predicts the development of MetS
and cardiovascular disease risk more than others.
Obstructive sleep apnea
Obstructive sleep apnea is commonly associated with obesity,
Hypertension, Increased cytokines, Impaired glucose tolerance and
Insulin resistance.
It is frequently seen in metabolic syndrome patients. continuous
positive airway pressure treatment improves Insulin sensitivity.
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Atherosclerosis
Inflammation is the bridging link between atherosclerosis &
metabolic syndrome.
Chronic inflammation? endothelial dysfunction. This facilitates
interaction between modified lipoproteins, monocyte derived
macrophages, T cells and normal cellular elements of vessel wall,
leading on to early and late atherosclerotic process.
Metabolic syndrome is a chronic low grade inflammatory
condition in which inflammation impairs insulin action through various
mechanisms. Other components of Metabolic syndrome also accelerates
atherosclerosis.26
Prothrombotic state.
Metabolic syndrome is associated with a significant increase in
the risk of developing prothrombotic state, due to disruption in the
balance of factors regulating coagulation and fibrinolysis 27
There is an increase in levels of many clotting factors Fibrinogen,
Factor VII, VIII, XII & XIIIB subunit.(jugan vague et al)28
Fibrinolytic system is relatively inhibited due to the increase in
levels of plasminogen - Activator Inhibitor I. Platelets in metabolic
syndrome patients are resistant to actions of Insulin, NitricOxide and
PG I2 thereby upregulating aggregation. All these, favour development
of hypercoagulable prothrombotic state enhancing cardiovascular
disease risk.
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Biomarkers of metabolic syndrome 29
Lipid and
lipoproteins
Low density
lipoprotein
Vascular injury
Adipokines
Leptin
Adiponectin
Resistin
Modulation of insulin
sensitivity .
Anti-inflammatory
action.
Impairment of glucose
tolerance.
Inflammatory
markers
C-reactive protein
TNF alpha receptor 2
Interleukin -6
Interleukin-8
Endothelial dysfunction
Insulin resistance
Athero thrombosis.
Chemokines Monocyte
chemotactic protein
Neutrophils attraction to
endothelium.
Haemostatic markers Plasminogen
activator inhibitor  1
Induction of cell
adhesion molecule
expression.
Insulin resistance.
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Concept of genes predisposing to metabolic syndrome
Mutations in the PPAR ? gene that disrupt the function of protein
causes severe IR,(savage et al 2003)30
dyslipidemia and Hypertension
Calpain 10 gene is important in modification and processing of
proteins in the cell.(sang et al)31
Variants in calpain gene alter the risk to Type 2 DM. Variants in
SUR & kir 6.2 cause rare diabetes related disorders & predispose to
Type 2 DM.32
Mutations  in  HNF1  ?.  HNF-4  ? and  rarely  in  GCK  gene  cause
MODY.
25
Genes causing metabolic syndrome
26
Lipoproteins are complexes of lipids and proteins that are essential for
the transport of cholesterol, triglyceride and fat soluble vitamins. It
contains a core of hydrophobic lipids  triglycerides and cholestryl esters
surrounded by hydrophilic lipids phospholipids and unesterified
cholesterol and proteins that interact with body fluids.33
Plasma lipoproteins are divided into five major classes based on
their relative density.
Chylomicrons
? Very low density lipoprotein
? Intermediate  density lipoprotein
? Low density lipoprotein
? High density lipoprotein.
HDL is the smallest and most dense lipoprotein, chylomicron and
VLDL are the largest and least dense lipoprotein.
The proteins associated with lipoproteins are called
apolipoproteins  they are required for the assembly structure and
function of lipoproteins.
APO A1 synthesized in the liver and intestine is found in all
HDL particles.
APO B 48 –contains chylomicrons
APO B 100-VLDL, IDL or LDL.
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Transport of dietary lipids
Exogenous  pathway 34
Dietary triglycerides are hydrolyzed by lipases within the
intestinal lumen and emulsified with bile acids.
Cholesterol and retinol are esterified to form cholestryl esters and
retinyl esters.
Longer chain fatty acids are incorporated into triglycerides and
packaged with APO B 48  cholestryl esters, phospholipids and
cholesterol to form chylomicrons.
Nascent chylomicrons are secreted into intestinal lymph and
delivered via thoracic duct to systemic circulation.
They become  chylomicrons when nascent particles combine
with apo CII and apo E derived from HDL.
The enzyme lipoprotein lipase present in capillary walls of
adipose tissue cardiac and skeletal muscle hydrolyses the
triacylglycerol present in chylomicrons and releases free fatty acids and
glycerol.
Lipoprotein lipase is activated by CII.
The chylomicron remnants are taken up by the receptors present
on the hepatocytes of the liver.
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Endogenous pathway 35
? VLDL particles resemble chylomicrons in protein composition
but contain APO B 100.
? Packaging of hepatic triglycerides with other components of
nascent VLDL particle require the action of MTP.
? Triglycerides are formed due to esterification of long chain fatty
acids in liver.
? After  secretion  into  the  plasma  VLDL  acquires  APO  CII  and
APO from HDL.
? VLDL are hydrolyzed by lipoprotein lipase especially in muscle
and adipose tissue.
? They lose APO CII after which IDL is formed.
? It loses APO E and gets converted to LDL.
? LDL contains high cholesterol and less triacylglycerol.
? the cholestrol  in LDL accounts for over half of the plasma
cholesterol in most individuals.
? Approximately 70% of LDL cholesterol is cleared by LDL
receptor mediated endocytosis in the liver.
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Investigations  to be done in case of metabolic syndrome
? Fasting lipid level
? Fasting glucose
? Liver function test.
? APO B
? High sensitivity –CRP
? Fibrinogen
? Uric acid
? Sleep study if obstructive sleep apnea is present
? Testosterone, luteinizing hormone, follicle stimulating hormone
in case of polycystic ovary disease.
? Urinary microalbumin.
30
Treatment of metabolic syndrome
Life style
Weight reduction is the primary approach to this disorder.
Recommendations for weight loss is calorie restriction, increased
physical activity, behavioural modification.36
Diet-
500 kcal restriction daily is adviced.diet restricted in
carbohydrate provide a rapid initial weight loss.
Physical activity
Increase in physical activity leads to weight reduction.60-90 min
of daily activity is required to achieve this goal.37
Obesity
Weight loss drugs can be used.drugs are phentermine and
sibutramine.orlistat inhibits fat absorption.bariatric surgery are other
options.38
LDL cholesterol
? Diet restricted in saturated fats.
? HMG COA reductase inhibitors are the first choice of drugs.
? Ezetimibe is the second choice.
? Bile acid sequestrants are more effective.
? cholestyramine and cholestipol.
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? Nicotinic acid
? Fenofibrates are the other drugs which can be used.
Triglycerides
Weight reduction
Gemfibrozil or fenofibrate is the drug of choice to lower fasting
triglycerides.39
Other drugs are statins nicotinic acid and omega 3 fatty acid
preparations.
HDL cholesterol
Nicotinic acid is the only available drug to raise HDL
cholesterol.
Blood pressure
In patients with metabolic syndrome without diabetes ACE
inhibitors or ARB are used.40
Impaired fasting glucose
Metformin has been showed to reduce the incidence of diabetes.
Insulin resistance Both metformin and thiazolidinediones increase
insulin sensitivity.
32
Blood supply of heart
Heart is supplied by two coronary  arteries arising from the
ascending aorta.both arteries run in the coronary sulcus.
Right coronary artery 41
Is smaller than the left coronary artery .it arises from the anterior
aortic aortic sinuses.
Branches
Large branches
Marginal
Posterior interventricular
Small branches
Nodal
Right atrial
Infundibular and terminal.
Area of distribution
Right atrium
Ventricles
Greater part of the right ventricle except the area adjoining the
anterior interventricular groove.
A small part of the left ventricle adjoining the posterior
interventricular groove. Posterior part of interventricular septum.
Whole of the conducting system of the heart except a part of the
left branch of AV bundle.
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Left coronary artery 42
Larger than the right coronary artery.arises from the left posterior
aortic sinus.
Branches
Large branches
Anterior interventricular
Branches to the diaphragmatic surface of left ventricle.
Diagonal branch.
Area of distribution
Left atrium
Ventricles
Greater part of the left ventricle except the area adjoining the
posterior interventricular groove.
A small part  of the right ventricle adjoining the anterior
interventricular groove.
Anterior part of the interventricular septum.
A part of left branch of AV bundle.
34
Acute coronary syndrome 43
They are patients whose clinical presentation cover the following
range of diagnosis.
ST segment elevation myocardial infarction
Non ST segment elevation MI
Unstable angina.
The first step is to a detailed description of the symptom complex
in order to characterize the chest pain or discomfort. Five descriptors
typically are considered.
1. Location,
2. Quality,
3. Duration of the discomfort,
4. Inciting factors, and
5. Factors relieving pain

35
Clinical classification of angina
Typical angina (definite)
1. Substernal chest discomfort with a characteristic quality and
duration that is
2. Provoked by exertion or emotional stress and
3. Relieved by rest or nitroglycerin.
Atypical angina (probable)
Meets two of the above characteristics.
Noncardiac chest pain
Meets one or none of the typical anginal characteristics.
Stable Angina:
Stable angina is characterized by a deep, poorly localized chest
or arm discomfort (rarely described as pain) that is reproducibly
associated with physical exertion or emotional stress and relieved
within 5 – 15 minutes by rest or sublingual nitroglycerine, or both. The
characteristics of the stable angina usually Unchanged for 60 days.
36
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Unstable angina is diagnosed mainly  based on clinical presentation. 45
Unstable angina is defined as angina pectoris or equivalent ischaemic
discomfort with atleast one of the three features.
It occurs at rest usually lasting for more than 10 minutes.
Severe and of new onset within the prior 4-6 weeks
Occurs with a crescendo pattern.
Diagnosis of NSTEMI is established if a patient with the clinical
features of unstable angina also has elevated cardiac biomarkers due to
myocardial necrosis.
Patho physiology
Plaque rupture or erosion.
Coronary spasm
Progressive mechanical obstruction.
Secondary unstable angina.
Clinical features
Chest pain typically located in the substernal region or
sometimes in the epigastrium that radiates to the neck, left shoulder.
Anginal equivalents such as dyspnea, fatigue, epigastric discomfort,
faintness and eructations..
Crescendo Angina: worsening of angina can be defined as
symptoms that result in at least 1 Canadian Cardiovascular Society
(CCS) class increase or to at least CCS Class 3 severity.
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Secondary Unstable Angina:
This form of unstable angina is precipitated by an imbalance in
myocardial oxygen supply and demand caused by condition extrinsic to
the coronary arteries in patients with prior coronary stenosis and
chronic stable angina.
Precipitating Factors
40
ST elevation MI: The classic World Health Organization criteria for an
acute MI 46 require that two of the following three elements be
present:
1. A history suggestive of coronary ischemia for a prolonged period
(>30 min),
2. Evolutionary changes in serial ECGs suggestive of MI, ST
segment elevation greater than 1mm in two contiguous limb
leads and greater than 2mm in two contiguous chest leads.
3. A rise and fall in serum cardiac markers consistent with
myonecrosis
The pain of myocardial infarction is typically substernal, diffuse,
with a squeezing or pressure quality. It may radiate to the neck or jaw,
shoulders, or arms. Most often, the pain is accompanied by additional
symptoms, such as lightheadedness, nausea or vomiting, diaphoresis, or
shortness of breath. The symptoms of myocardial infarction last longer
than 30 minutes, and do not respond completely to nitroglycerin.
Elderly or diabetic patients are prone to atypical symptoms, such as
nausea or dyspnea as the sole symptoms of infarction. As many as one-
fourth of myocardial infarctions are “silent” — that is, whatever
symptoms were present did not impress the patient enough to seek
medical care, or even to remember the incident.
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MATERIALS AND METHODS
METHODOLOGY:
Patients with unstable angina, STEMI and NSTEMI were
evaluated for metabolic syndrome using NCEP ATPIII guidelines.
Waist circumference was measured at the narrowest point with
stomach relaxed.
Blood samples were collected for fasting blood sugar with
overnight fasting.
Blood samples were collected for lipid profile with 12 hours
overnight fasting.
Blood pressure was recorded in right upper limb in sitting
posture.
BACKGROUND
Metabolic syndrome consist of a cluster of metabolic and
haemodynamic disorders that promote the development of
atherosclerosis. The presence of metabolic syndrome has been
positively correlated with cardiovascular  risk. The prevalence of
metabolic syndrome was assessed using NCEP III.
42
STUDY DESIGN:
Prospective non randomized case series.
STUDY POPULATION:
About 100 patients admitted in intrinsic coronary care unit.
INCLUSION CRITERIA:
All patients with STEMI,NSTEMI and unstable angina.
EXCLUSION CRITERIA:
Patients with preexisting valvular heart disease was excluded from the
study.
43
RESULTS AND ANALYSIS
Metabolic syndrome
PRESENT ABSENT TOTAL
MALE 21 49 70
FEMALE 12 18 30
P value not significant.
This table shows that the study was done in 70 males and 30 females .
There was a sex predilection in females when compared to males.p
value was calculated using chi square test it was not significant.
SEX PREVALENCE IN METABOLIC SYNDROME
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FASTING BLOOD SUGAR AND METABOLIC SYNDROME
PRESENT ABSENT TOTAL
Fasting blood
sugar <100
0 22 22
Fasting blood
sugar >100
33 45 78
P  value <0.001
Fasting blood sugar values were compared in both patients with
metabolic syndrome and with no metabolic syndrome .out of 33
patients with metabolic syndrome all 33 had elevated blood sugar
values greater than 100 mgs%.In non metabolic syndrome group 44
patients had elevated blood sugar out of 67 patients.the percentage was
100% in patients with metabolic syndrome when compared with 65% in
patients without metabolic syndrome it revealed a significant p value.
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BLOOD PRESSURE AND METABOLIC SYNDROME
PRESENT ABSENT TOTAL
BP<130/85 7 50 57
BP>130/85 26 17 43
P value <0.001
Blood pressure was elevated more than the cut off value in  26
patients out of 33 patients with metabolic syndrome.17 patients out 67
had elevated blood pressure in  patients without metabolic syndrome.
The difference between the two groups were 78% in patients with
metabolic syndrome and 25% in patients without metabolic syndrome.
p value revealed a significant value.
BLOOD PRESSURE AND METABOLIC SYNDROME
7
50
26
17
0
10
20
30
40
50
60
PATIENTS WITH MS NORMAL
Number of Persons
NO HIGH BP
HIGH BP
46
TRIGLYCERIDES AND METABOLIC SYNDROME
PRESENT ABSENT TOTAL
TRIGLYCERIDE
>150
21 8 29
TRIGLYCERIDE
<150
12 59 71
P value less than 0.001
Out of the 100 patients 21 patients had elevated triglyceride levels
among 33 patients with metabolic syndrome and 8 patients with no
metabolic syndrome among  67 patients. The difference between the
two groups were 63%versus 13%In patients without metabolic
syndrome. p value was significant.
TRIGLYCERIDE AND METABOLIC SYNDROME
12
59
21
8
0
10
20
30
40
50
60
70
PATIENTS WITH MS NORMAL
Number of Persons
TRIGLYCERIDE <=150
TRIGLYCERIDE >150
47
HDL AND METABOLIC SYNDROME
PRESENT ABSENT TOTAL
HDL >50 0 22 22
HDL < 50 33 45 88
P value <0.001
Out of 100 patients studied with metabolic syndrome 33patients
had HDL levels lesser than 50 mgs%. in patients without metabolic
syndrome 45 patients had HDL levels lesser than50 mgs%.
Patients with  metabolic syndrome showed100% when compared with
65% in patients  without metabolic syndrome.
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WAIST CIRCUMFERENCE AND METABOLIC SYNDROME
PRESENT ABSENT TOTAL
WAIST
CIRCUMFERENCE
INC
22 60 72
WAIST
CIRCUMFERENCE
NORMAL
11 7 18
P value <0.001
Waist   circumference  was  increased  in  22  out  of  33  patients  with
metabolic syndrome  when compared to 60 out of 67 in patients without
metabolic syndrome. Waist circumference in patients with  metabolic
syndrome was 66% when compared to 89% in patients without
metabolic syndrome. p value was significant and was less than  0.001.
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FACTORS B STANDARD
ERROR
SIGNIFICANCE
FBS -20.436 7569.02 .998
BP -2.354 0.684 .001
TRIGLYCERIDES -1.401 0.703 .046
HDL -19.801 7737.78 .998
WAIST
CIRCUMFERENCE
-1.511 0.848 .075
The components highly influencing the occurrence of metabolic
syndrome was studied by applying logistic regression method. .out of
the 100 patients studied triglycerides and blood pressure were the two
variables that were statiscally significant highly influencing the
occurrence of metabolic syndrome.
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PREVALENCE OF EACH COMPONENT OF METABOLIC
SYNDROME
Yes No
Fasting blood sugar >
100
100% 67%
Blood pressure>130/85 78% 25%
Triglycerides>150mg/dl 63% 13%
HDL<50 mg/dl 100% 65%
Waist circumference
increased
66% 89%
Out of the 100 patients studied  in patients with metabolic syndrome all
had elevated blood sugar values contributing to 100%. 26 patients had
high blood pressure out of 33  contributing to 78%.21 patients had
elevated triglycerides out of 33 contributing to 63%.all 33 patients  had
low HDL levels yielding 100%.22 patients had increased waist
circumference out of 33 patients contributing 66%.
All patients showed statiscal significance confirming strong association
with metabolic syndrome.
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DISCUSSION
Prevalence of metabolic syndrome is highly prevalent in acute
coronary syndrome patients. (Solymon BC, Bourassa MG, Campeau) 47
et al on their study on  effect of increasing metabolic syndrome score
on atherosclerotic risk profile and coronary artery disease.
Angiographic severity have shown an increased prevalence of
metabolic syndrome 51% in their study. Similar prevalence rate was
also shown by mariam zeller and coworkers in their studies.
Increased prevalence of metabolic syndrome in patients with
acute coronary syndrome is also shown by two studies one conducted
in middle east countries in 2010 showed a prevalence of 46% and
other in kaunos medical university in 2008 showed a prevalence of
60%.
100  patients were studied to find out the prevalence of metabolic
syndrome in patients with acute coronary syndrome .The patients were
evaluated using NCEP ATP III guidelines.
75 patients with myocardial infarction, 15 patients with non
STEMI, 10 patients with unstable angina were studied for the
prevalence of metabolic syndrome.
The study was done in 70 females and 30 males. P value was
calculated to find out the %   of both sex contributing to  metabolic
syndrome using chi square test .p value was of no significance.there
was female predilection when compared to males.
Fasting  blood sugar values were compared in both patients with
metabolic syndrome and with no metabolic syndrome.. out of 33
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patients with metabolic syndrome  all 33 had elevated blood sugar
values greater than 100 mg%. In non metabolic syndrome group 44
patients had elevated blood sugar out of 67 patients. the percentage was
100% in patients with metabolic syndrome  when compared with 65in
patients with absent metabolic syndrome.It revealed a significant p
value. This study is supported by mariamme zeller in their study 48 out
of 290 metabolic syndrome patients had increased fasting glucose in
contrast to 20 out of 343 non metabolic syndrome patients.
Hypertension is particularly dangerous .This concept is supported
by the Framingham heart study. Blood pressure was elevated more than
the cut off value in  26 patients out of 33 patients with metabolic
syndrome.17 patients out 67 had elevated blood pressure in  patients
without metabolic syndrome. The difference between the two groups
were 78% in patients with metabolic syndrome and 25% in patients
without metabolic syndrome. p value revealed a significant value.
This study is consistent with zeller study 48 which shows 228
out of 290 in the metabolic syndrome group and 99 0ut of 343 in non
metabolic syndrome patients. This study is also similar to studies
conducted by ramachandran et al in 2003 in urban asian adults.49
Out of the 100 patients 21 patients had elevated triglyceride
levels  among 33 patients with metabolic syndrome and 9 patients with
no metabolic syndrome among  67 patients. The difference between the
two groups were 63%versus 13 % in patients without metabolic
syndrome. p value was significant.
In the zeller study 48 elevated triglycerides was found in 57%  of
metabolic syndrome patients to that of 14% in the non metabolic
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syndrome group. this study is also similar to  the study conducted by
gupta et al in 2003 prevalence of  metabolic syndrome in urban
Indian population.50
Out of 100 patients studied with metabolic syndrome 33patients
had HDL levels lesser than 50 mgs%. in patients without metabolic
syndrome 45 patients had HDL levels lesser than 50 mgs% patientswith
metabolic syndrome showed100% when compared with 65% in patients
without metabolic syndrome.
Low HDL is a significant  risk factor MI as shown by zeller study 48 in
which 80% in metabolic syndrome group 22% in non metabolic
syndrome group had low HDL levels.
Waist  circumference was increased in 22 out of 33 patients with
metabolic syndrome  when compared to 60 out of 67 in patients without
metabolic syndrome. Waist circumference in patients with  metabolic
syndrome was 66% when compared to 89% in patients without
metabolic syndrome. p value was significant and was less than  0.001.
in the zeller study 48 290 patients of metabolic syndrome group had
high waist circumference when compared to 94 out of 343 non
metabolic syndrome patients.
Out of the 100 patients studied triglycerides and blood pressure
were the two variables that were statistically significant highly
influencing the occurrence of metabolic syndrome. This was found by
applying  logistic regression method. Triglycerides had the highest
positive predictive value in a study conducted  in middle east
countries51 in 2010 and in a study conducted in 2008 at maulana azad
medical college in Delhi.
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Limitations of the study
Our data was collected from an observational study which is a
limitation.
The fundamental limitations of observational studies cannot be
eliminated because of the non randomized nature and unmeasured
confounding factors.
However well designed observational studies provide valid
results compared to the results of randomized  control trial
TOTAL PREVALENCE OF METABOLIC SYNDROME
33
67
MS
No MS
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Conclusion
Among 100 patients studied for the prevalence of metabolic
syndrome in patients with acute coronary syndrome the overall
prevalence was 33% . There was predilection in females when
compared to males.
Triglycerides and blood pressure highly influenced the
occurrence of metabolic syndrome.
All patients showed statistical significance confirming strong
association with acute coronary syndrome.
It was also associated with increased risk of recurrent myocardial
infarction. Metabolic syndrome is associated with higher risk
characteristics and increased risk for the development of  heart failure
without increase in hospital mortality. So to  prevent the complications
due to metabolic syndrome there is a need for early and intensive
preventive measures.
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PREVALENCE OF METABOLIC SYNDROME IN PATIENTS
WITH ACUTE CORONARY SYNDROME AT GSH CHENNAI.
PATIENT NAME : AGE / SEX:
ADDRESS : I.P.NO.:
UNIT :
PHONE NO.:
DOA : DOD : WT:
HT:
Admission clinical diagnosis :
BMI :
RISK FACTOR : DM / SHT / CAD / CVA / CKD / PVD
: Family h/o : Y/No
: Smoker :  Y/No
: Alcoholic :  Y/No.
LIPID PROFILE : TC      LDL HDL      TG           VLDL
BLOOD SUGER  :         RBS        FBS            PPBS
BLOOD UREA
CREATININE
Waist Circumference : Blood
Grouping
ECG :
ECHO :
Other relevant Inv :
63
ABBREVIATIONS
MS-METABOLIC SYNDROME
STEMI-ST ELEVATION MI
NSTEMI-NON ST ELEVATION MI
FBS-FASTING BLOOD SUGAR
BP-BLOOD PRESSURE
TG-TRIGLYCERIDES
WC-WAIST CIRCUMFERENCE
HDL-HIGH DENSITY LIPOPROTEIN
VLDL-VERY  LOW DENSITY LIPOPROTEIN
TNF-TUMOUR NECROSIS FACTOR
PAI-PLASMINOGEN ACTIVATOR INHIBITOR
NEFA-NON ESTERIFIED FATTY ACIDS
NAME AGE IP.NO DM HT FBS BP TG HDL W.C M.S
THIRUNAVUKARASU 80 33979 YES NO 142 110/70 108 20 98 2
PARAMANANDHAM 55 33669 NO YES 126 160/100 249 22 78 1
AMBIGA 70 38615 NO NO 90 130/90 138 38 93 2
ARUNAGIRI 55 38660 YES NO 251 110/70 112 25 104 1
INDIRANI 50 38662 YES YES 190 200/100 164 34 102 1
ARUMUGAM 70 33975 NO YES 113 180/110 238 30 96 1
MADIVANAN 40 38218 YES NO 144 130/100 104 50 64 2
MURUGESAN 45 38456 NO NO 135 140/90 258 26 83 1
DHANSEKAR 58 38449 NO NO 76 130/100 130 24 74 2
SUBRAMANIYAM 35 38553 YES NO 159 130/90 116 46 88 2
JEYARAMAN 58 37190 NO NO 86 120/80 140 22 84 2
THIRUNAVUKARASU 58 37192 NO NO 121 130/90 144 44 83 2
THIYAGARAJAN 49 38058 NO NO 142 110/70 164 34 90 2
AHAMADULLAH 58 38445 YES NO 311 110/70 158 22 104 1
KOTHANDAPANI 82 38491 NO NO 92 120/80 112 22 75 2
GOPAL 72 22686 NO YES 102 130/90 127 58 97 2
MEERA 56 38530 NO YES 98 170/100 110 62 88 2
ARUMUGAM 35 30395 NO YES 106 180/110 133 40 70 2
THARA 50 38395 YES YES 500 180/120 148 28 98 1
CHINNASWAMY 63 22687 NO YES 112 160/90 132 32 92 1
PONNUSWAMI 65 38167 YES NO 159 120/80 116 36 85 2
VIJAYALAKSHMI 54 22456 NO YES 123 180/100 121 28 62 1
MARY 58 38185 NO YES 118 170/90 128 30 90 1
DHIVYA 75 38958 NO NO 103 130/90 144 26 87 1
FRANCIS 50 25836 NO YES 102 180/90 177 32 87 1
GOPAL 60 25177 NO NO 110 130/80 98 48 72 2
TAMIZH 55 18585 NO NO 142 110/70 99 27 83 2
MANOHAR 60 19517 NO YES 138 150/80 132 42 84 2
SAMBATH 55 18584 NO NO 114 120/80 116 45 74 2
RAMALINGAM 45 18583 NO NO 131 130/90 92 44 66 2
PALANI 50 18452 YES YES 293 140/90 174 24 78 1
ISRAEL 60 36717 NO NO 99 110/70 96 38 76 2
ARULRAJ 62 34013 NO NO 93 110/70 90 36 70 2
GOUSEBEE 60 19517 NO NO 132 120/80 112 24 84 2
MUTHU 54 18567 NO YES 130 150/90 188 36 88 1
KRISHNAVENI 50 18585 NO NO 142 140/90 138 38 94 1
SENTHIL KUMAR 65 37567 YES NO 233 110/70 154 25 102 1
PARUSURAMAN 52 38798 YES YES 184 180/100 174 34 98 1
NARAYANAN 45 37798 NO YES 112 170/100 212 40 96 1
SURESH 65 18595 NO NO 138 130/100 104 48 70 2
SUNAMBEE 48 18594 NO NO 134 140/90 254 28 88 1
ANNAMALAI 70 18345 NO NO 72 120/80 128 32 78 2
MALLIGA 48 37132 YES NO 154 130/90 132 46 90 2
JEYARAMAN 68 37190 NO NO 84 120/80 138 28 84 2
VENKATESAN 60 37799 NO NO 124 130/90 148 42 85 2
JEYARAMAN 65 37733 NO YES 148 150/90 168 30 90 2
KANNAN 62 37826 YES NO 315 110/70 174 24 96 2
SURESH 35 38765 YES YES 170 150/90 212 28 88 1
KANNAIAH 65 33056 YES YES 220 140/90 164 24 104 1
KUMARAN 42 34561 NO NO 90 130/90 114 26 76 2
RAJESH 55 38642 NO NO 104 140/90 129 56 100 2
VIJAYA 36 34562 NO YES 90 160/100 112 64 90 2
KUMARAVEL 67 15892 NO YES 106 170/100 136 38 74 2
KRISHNAVENI 45 37264 YES YES 468 180/100 154 22 98 1
MURUGAN 50 31253 NO YES 114 150/90 136 44 86 2
DHINAKARAN 70 17573 YES NO 160 130/90 116 34 86 1
LAKSHMI 45 19853 NO NO 125 140/90 168 28 88 2
MINIYANDI 50 21543 NO YES 120 160/100 132 40 90 2
RAJAPUSHPAM 67 15873 NO NO 102 120/80 144 26 88 2
KARPAGAM 65 19783 NO YES 104 170/100 168 32 90 1
EKAMBARAM 72 37985 NO NO 110 130/80 96 48 74 2
CHINNASWAMY 54 17893 NO NO 140 110/70 98 26 84 2
GOVINDASWAMY 49 23546 NO NO 136 110/70 134 30 86 2
AMUDHA 53 38954 NO NO 116 130/90 118 46 76 2
RAJARAMAN 54 19847 NO NO 130 130/90 94 44 70 2
GNANASUNDAR 57 23456 YES NO 280 140/90 178 26 80 1
MAHESWARI 70 25678 NO NO 100 110/70 98 36 78 2
VELU 67 30789 NO NO 96 110/70 94 34 72 2
PADMAVATHY 55 30413 NO NO 146 130/80 112 24 98 2
AROKIASWAMY 56 17654 NO NO 124 120/80 228 26 80 2
GOVINDARAJ 49 24586 NO NO 134 120/80 142 36 92 2
MARIAMMAL 62 17589 YES NO 242 110/70 132 26 90 1
BABU 45 21679 YES NO 198 210/100 172 28 102 1
RAJA 50 14567 NO YES 102 160/100 218 28 98 1
PANNERSELVAM 63 26453 NO NO 138 130/90 106 48 72 2
PRAKASAM 54 13456 YES NO 142 110/70 260 28 84 2
RATHINAVEL 67 35678 NO NO 78 120/80 124 26 76 2
CHANDRA 49 29867 YES NO 160 140/90 118 48 90 1
MOHAN 49 31535 NO YES 92 170/100 142 24 85 2
SURESH 74 19537 NO NO 116 120/80 138 42 83 2
MADHAVAN 54 18756 NO NO 94 110/70 114 24 76 2
DHARMARAJ 69 37564 NO NO 104 130/90 125 59 95 2
RAMESH 70 14325 NO YES 98 160/100 114 58 88 2
SUBRAMANIYAM 65 26745 YES YES 424 170/100 145 28 97 1
KUMAR 50 34567 NO NO 93 140/90 135 37 95 2
RADHAKRISHNAN 53 30567 YES YES 162 150/90 117 39 86 2
SHIVAKUMAR 56 40234 NO NO 125 120/80 125 28 70 2
MUTHUKUMAR 70 31234 NO YES 121 180/100 131 33 92 1
JAYANTHI 52 10789 NO NO 95 130/90 145 26 88 2
KRISHNAKUMAR 47 36785 NO YES 110 170/100 175 34 90 1
RAVINDRAN 57 26758 NO NO 118 120/80 108 46 74 2
RAJARAMAN 45 21234 NO NO 96 110/70 96 34 76 2
SARASWATHI 62 17854 NO NO 130 120/80 114 26 98 2
MURUGANANDAM 46 30752 NO NO 128 110/70 184 38 90 2
NAGALAKSHMI 39 30175 NO NO 140 130/90 136 40 86 2
VEDACHALAM 45 32134 YES NO 220 110/70 164 28 100 1
JEYAVEL 53 17890 NO YES 90 170/100 178 32 96 2
THULASI 55 13508 NO NO 92 140/90 148 38 84 2
PARVATHI 59 30475 NO NO 98 130/90 134 54 88 2
KARPAGAM 50 14575 NO NO 95 110/70 132 52 88 2
